Abstract Ixazomib is an oral proteasome inhibitor used in combination with lenalidomide plus dexamethasone (IXA-LEN-DEX) and licensed for relapsed or refractory multiple myeloma. As part of a single technology appraisal (ID807) undertaken by the National Institute of Health and Care Excellence, the Evidence Review Group, Warwick Evidence was invited to independently review the evidence submitted by the manufacturer of ixazomib, Takeda UK Ltd. The main source of clinical effectiveness data about IXA-LEN-DEX came from the Tourmaline-MM1 randomized controlled trial in which 771 patients with relapsed or refractory multiple myeloma received either IXA-LEN-DEX or placebo-LEN-DEX as their second-, third-, or fourth-line treatment. Takeda estimated the cost effectiveness of IXA-LEN-DEX using a de-novo partitioned-survival model with three health states (pre-progression, post-progression, and dead). In their first submission, this model was used to estimate the cost effectiveness of IXA-LEN-DEX vs. bortezomib plus dexamethasone (BORT-DEX) in second-line treatment, and of IXA-LEN-DEX vs. LEN-DEX in third-line treatment. To estimate the relative clinical performance of IXA-LEN-DEX vs. BORT-DEX, Takeda conducted network metaanalyses for important outcomes. The network meta-analysis for overall survival was found to be flawed in several respects, but mainly because a hazard ratio input for one of the studies in the network had been inverted, resulting in a large inflation of the claimed superiority of IXA-LEN-DEX over BORT-DEX and a considerable overestimation of its cost effectiveness. In subsequent submissions, Takeda withdrew second-line treatment as an option for IXA-LEN-DEX. The manufacturer's first submission comparing IXA-LEN-DEX with LEN-DEX for third-line therapy employed Tourmaline-MM1 data from third-and fourth-line patients as proxy for a third-line population. The appraisal committee did not consider this reasonable because randomization in Tourmaline-MM1 was stratified according to one previous treatment and two or more previous treatments. A further deficiency was considered to be the manufacturer's use of interim survival data rather than the most mature data available. A second submission from the company focussed on IXA-LEN-DEX vs. LEN-DEX as third-or fourth-line treatment (the two or more previous lines population) and a new patient access scheme was introduced. Covariate modeling of survival outcomes was proposed using the most mature survival data.
IXA-LEN-DEX or placebo-LEN-DEX as their second-, third-, or fourth-line treatment. Takeda estimated the cost effectiveness of IXA-LEN-DEX using a de-novo partitioned-survival model with three health states (pre-progression, post-progression, and dead). In their first submission, this model was used to estimate the cost effectiveness of IXA-LEN-DEX vs. bortezomib plus dexamethasone (BORT-DEX) in second-line treatment, and of IXA-LEN-DEX vs. LEN-DEX in third-line treatment. To estimate the relative clinical performance of IXA-LEN-DEX vs. BORT-DEX, Takeda conducted network metaanalyses for important outcomes. The network meta-analysis for overall survival was found to be flawed in several respects, but mainly because a hazard ratio input for one of the studies in the network had been inverted, resulting in a large inflation of the claimed superiority of IXA-LEN-DEX over BORT-DEX and a considerable overestimation of its cost effectiveness. In subsequent submissions, Takeda withdrew second-line treatment as an option for IXA-LEN-DEX. The manufacturer's first submission comparing IXA-LEN-DEX with LEN-DEX for third-line therapy employed Tourmaline-MM1 data from third-and fourth-line patients as proxy for a third-line population. The appraisal committee did not consider this reasonable because randomization in Tourmaline-MM1 was stratified according to one previous treatment and two or more previous treatments. A further deficiency was considered to be the manufacturer's use of interim survival data rather than the most mature data available. A second submission from the company focussed on IXA-LEN-DEX vs. LEN-DEX as third-or fourth-line treatment (the two or more previous lines population) and a new patient access scheme was introduced. Covariate modeling of survival outcomes was proposed using the most mature survival data. The Evidence Review Group's main criticisms of the new evidence included: the utility associated with the pre-progression health state was overestimated, treatment costs of ixazomib were underestimated, survival models were still associated with great uncertainty, leading to clinically implausible anomalies and highly variable incremental cost-effectiveness ratio estimates, and the company had not explored a strong assumption that the survival benefit of IXA-LEN-DEX over LEN-DEX would be fully maintained for a further 22 years beyond the observed data, which encompassed only approximately 2.5 years of observation. The appraisal committee remained unconvinced that ixazomib represented a cost-effective use of National Health Service resources. Takeda's third submission offered new basecase parametric models for survival outcomes, a new analysis of utilities, and proposed a commercial access agreement. In a brief critique of the third submission, the Evidence Review Group agreed that the selection of appropriate survival models was problematic and at the request of the National Institute for Health Care and Excellence investigated external sources of evidence regarding survival outcomes. The Evidence Review Group considered that some cost and utility estimates in the submission may have remained biased in favor of ixazomib. As a result of their third appraisal meeting, the committee judged that for the two to three prior therapies population, and at the price agreed in a commercial access agreement, ixazomib had the potential to be cost effective. It was referred to the Cancer Drugs Fund so that further data could accrue with the aim of diminishing the clinical uncertainties.
Key Points for Decision Makers
Ixazomib combined with lenalidomide and dexamethasone has been approved by the European Medicines Agency for patients with multiple myeloma who had received at least one prior therapy based on positive outcomes on progression-free survival when compared to placebo with lenalidomide and dexamethasone. The data on overall survival are not sufficiently mature to draw any meaningful conclusions on this outcome measure Ixazomib combined with lenalidomide and dexamethasone is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults only if they have previously received two or three lines of therapy and if the conditions in the managed access agreement for ixazomib have been followed When the outcome estimates derived from network meta-analyses appear clinically implausible, it becomes doubly important that network metaanalysis input data be thoroughly scrutinised When Kaplan-Meier curves are immature, there is considerable uncertainty around the overall survival and progression-free survival estimates, and a partitioned survival model does not impose any functional relationship upon these estimates. The plausibility of overall survival and progression-free survival extrapolations can be further assessed by examining the relative balance between preprogression survival gain and post-progression survival gain, together with the balance between preprogression survival and post-progression survival within each treatment strategy
Introduction
The National Institute for Health Care and Excellence (NICE) is an independent body responsible for appraising licensed medical interventions and issuing guidance on their use within the UK National Health Service (NHS Most patients with MM eventually relapse after an initial therapy; patients may harbor multiple clones of MM cells and therefore may require further treatment. The choice of subsequent treatment depends on several factors including type of previous treatment, a new regimen's capacity to induce a good response, its tolerance, and its ease of administration. Targeting several MM sub-clones at once is the rationale for using combination therapies in MM. In recent years, a number of novel agents have become available including proteasome inhibitors (BORT, carfilzomib, IXA) and immunomodulatory drugs (thalidomide, LEN, pomalidomide), but not all combinations of options are currently recommended within the NHS. To date, the therapies combining novel drugs with different mechanisms of action used within the UK are mainly limited to first-line treatment of MM with BORT plus thalidomide combined with DEX. In contrast to some other combination regimens, IXA-LEN-DEX is an all-oral therapy and Takeda proposed that this represented a distinct advantage for patients with RRMM and health service providers.
The company's major source of evidence was the Tourmaline MM1 (TMM-1) randomized controlled trial (RCT) [4] in which 771 patients with RRMM received either IXA-LEN-DEX or placebo-LEN-DEX as their second-, third-, or fourth-line treatment. In their first submission, the company located IXA-LEN-DEX as a second-or third-line therapy in the treatment pathway. This excluded patients who had already received three lines of therapy.
The comparators considered by the company were: (1) BORT with DEX (BORT-DEX) for second-line therapy and (2) LEN with DEX (LEN-DEX) for third-line therapy. Thus, in second-line treatment, the company excluded LEN-DEX as well as BORT monotherapy or BORT retreatment, as potential comparators. The manufacturer's reasons for second -line LEN-DEX exclusion were an interim negative ACD issued from NICE and its lack of funding under the Cancer Drugs Fund (CDF). If IXA-LEN-DEX is positioned as a second-line agent, it appears illogical that LEN-DEX itself is not considered a comparator. Furthermore, the ERG's clinical advice was that LEN-DEX can sometimes be used as a second-line treatment in NHS practice; additionally, Takeda itself noted that the market share for LEN-DEX is appreciable (at * 26%), implying quite frequent use. However, these data may not have reflected the recent exclusion of second-line LEN from the CDF. The ERG considered the exclusion of BORT monotherapy to be reasonable because it is very rarely used as a single agent. The company excluded BORT retreatment on the grounds that it was not funded by NHS England; however, the ERG's clinical advice was that some centers do employ this treatment while others do not. The company's selection of BORT-DEX as the only second-line comparator forced the use of indirect treatment comparisons, estimated using a network meta-analysis (NMA), in comparing the relative merits of IXA-LEN-DEX with BORT-DEX, whereas if LEN-DEX had been the comparator, direct evidence from the manufacturer's own RCT could have been used.
For third-line treatment (first submissions), the company excluded panobinostat-BORT-DEX (PAN-BORT-DEX) as a potential comparator on the grounds of its predominant use as a fourth-line therapy. For patients with RRMM who have received at least two prior regimens including BORT and an immunomodulatory drug, NICE recommends PAN-BORT-DEX; thus, in the ERG's opinion it represents a third-line option, and its exclusion was not justified.
Company's Original Submission and Outcome
Following First Appraisal Committee
Submitted Clinical Evidence and Evidence Review Group Critique
The company's literature search and systematic review identified 14 relevant studies. These studies provided data for input into NMAs to indirectly estimate the relative clinical effectiveness of IXA-LEN-DEX vs. BORT-DEX in second-line treatment.
The ERG considered that TMM-1 [4] was of good quality, with a low risk of bias in most domains. Progression-free survival (PFS), estimated at the first interim analysis (median follow-up * 15 months), was the prespecified primary outcome.
1 Pre-specified secondary endpoints included overall survival (OS), overall response rates, and health-related quality of life.
In the entire TMM-1 population, the hazard ratio (HR) of PFS for IXA (first interim analysis at 15 months followup) suggested a 26% reduction in risk [HR 0.74, 95% confidence interval (CI) 0.5-0.94; p = 0.012], which led to marketing approval of IXA. At a later data cut (23 months median follow-up), analysis showed a smaller treatment effect of an 18% risk reduction (HR 0.82, 95% CI 0.67-1.0; p = 0.054). Thus, an initially observed benefit in the first interim analysis did not persist through the second interim analysis. This was one of the reasons for an initial negative opinion provided by the Committee for Medicinal Products for the marketing authorization. However, the company argued that the more mature analysis was noninferential (added as a late amendment of the study protocol), and that according to the pre-specified statistical analysis plan, a PFS benefit had been demonstrated. The Committee for Medicinal Products revised their initial opinion and decided in favor of market approval. The ERG noted that a statistically significant difference in PFS with immature data was followed by no statistically significant difference on PFS when more mature data were available.
The HR for OS in patients treated with IXA compared with those receiving placebo was similar in the first (HR for death 0.90, 95% CI 0.62-1.32) and second (HR 0.87, 95% CI 0.64-1.18) interim analyses. In the one prior therapy population (second-line therapy), the TMM-1 trial showed no statistically significant benefit of IXA in PFS or in OS. In the two or more prior therapies population (thirdand fourth-line therapy), the benefit of IXA was greater than in second line in PFS. Overall survival benefit with IXA requires confirmation with more mature data. 2 Consistent with the NICE scope, the company presented separate analyses according to the number of prior therapies (one or two prior therapies/three prior therapies). As described above, Takeda selected BORT-DEX and not LEN-DEX as the comparator for second-line treatment and thus undertook NMAs to determine if any relative benefit derived from the use of IXA-LEN-DEX. Table 1 (Fig. 1) . The ERG therefore investigated if the OS performance of BORT-DEX suggested from the company's NMA-based economic modeling tallied with that observed in the four BORT-DEX studies the company input into its NMA. To do this, the ERG employed published KM plots and the method of Guyot et al. [6] to reconstruct the individual participant data within the four studies and to develop parametric models. Figure 2 summarizes the results and shows a large discrepancy between the 'observed' OS under BORT-DEX and the company's model, which was derived by applying the NMA HR of 2.97 to an exponential model of OS for second-line patients in the LEN-DEX arm of the TMM-1 RCT (note that in TMM-1, 69% of patients had already previously been treated with BORT).
The ERG identified a major error in the company's HR inputs for their OS NMA, which accounts for the erroneous BORT-DEX vs. LEN-DEX and BORT-DEX vs. IXA-LEN-DEX results. In its OS NMA, the company's HR input for death with DEX vs. BORT was 0.57, while in fact, as reported in the APEX trial [7] , 0.57 corresponded to the inverse HR for death for BORT vs. DEX.
Using the same methods as for OS, the ERG similarly investigated whether the PFS performance of BORT-DEX suggested from the company's NMA modeling tallied with that observed in the four BORT-DEX studies the company input into its PFS NMA. The results (Fig. 2) suggest that Takeda's model of PFS for BORT-DEX is overoptimistic. By apparently overestimating BORT-DEX PFS and underestimating BORT-DEX OS, the company models squeeze the difference between OS and PFS (equivalent to post-progression survival) to a relatively small proportion of OS when compared with that 'observed' in BORT-DEX studies. The rather large proportion of survival seen after progression in the four primary studies testing the 1 Progression-free survival was defined as the time from the date of randomization to the date of first documentation of disease progression, based on central laboratory results and International Myeloma Working Group criteria as evaluated by an independent review committee, or death as a result of any cause, whichever occurred first. 2 Hazard ratio values are not reported because these were marked as confidential by the company at the time of the appraisal.
Table 1
Study characteristics of network meta-analysis (NMA) studies used to link ixazomib-lenalidomide-dexamethasone (IXA-LEN-DEX) to bortezomib-dexamethasone (BORT-DEX) effectiveness of BORT-DEX may partly reflect the use of subsequent treatments after progression.
Following the identification of the error in the company's NMA, the ERG undertook a number of exploratory analyses on the clinical effectiveness estimates for the indirect comparison of IXA-LEN-DEX with BORT-DEX. The ERG undertook random-effects NMAs using the program 'network' in Stata [8] . In patients with at least one prior therapy, which was used as a proxy source for patients with one prior therapy, the ERG's HR estimates for PFS and OS were 0.75 (95% CI 0.41-1.38) and 0.91 (95% CI 0.43-1.92), respectively.
Examination of the company's NMAs revealed several deviations from common practice. Indeed, the ERG has identified several methodological flaws in the NMA, in particular focusing on the assumptions of homogeneity, similarity, and consistency. The transitivity assumption was violated because the distribution of population characteristics that are effect modifiers differs across the treatment comparisons of the network (Table 1) . One such treatment effect modifier in the company's NMAs is the number of prior therapies. While the TMM-1 trial included around 60% patients at the first relapse, the MM-009 [9] and MM-010 [10] studies included around 60-65% of patients with two prior therapies. The Dimopoulos et al. Fig. 1 Relationship between progression-free survival (PFS) and overall survival (OS) hazard ratios (HRs) in randomized controlled trials of interventions for multiple myeloma. Hollow circles indicate data digitised from Cartier et al. [5] . Diamonds indicate Tourmaline MM1 patients: all; second line, third line, and third or fourth line. The solid circle indicates results from the company's network metaanalysis (NMA). bort-dex bortezomib-dexamethasone, CS company submission, ixa-len-dex ixazomib-lenalidomide-dexamethasone, 1 ? prior patients with at least one prior therapy indirectly compared treatments, the more unreliable this comparison becomes, through increasing the standard error of the effect estimate. As a result, the validity of the OS-HR estimate for the indirect comparison IXA-LEN-DEX vs. BORT-DEX was questionable. The NMA did not form any closed loops. Understandably, consistency between indirect and direct comparisons was not assessed. Indeed, this is one of the main limitations of the evidence provided in the NMAs of the manufacturer's submission owing to the inability to judge to what degree the statistical dimensions of the transitivity assumption were violated.
OS HR PFS HR
Randomized controlled trials and observational studies were both included in the same NMA. In the PFS NMA, the company used the observational study Montefusco et al. [12] , which compared BORT-DEX plus cyclophosphamide with LEN-DEX plus cyclophosphamide to connect the network between BORT-DEX and LEN-DEX. These aspects, taken together with an incorrect HR input into the NMA for OS, seriously challenge the validity of the NMA results.
Submitted Cost-Effectiveness Evidence and Evidence Review Group Critique
The company developed a partitioned survival model with a weekly cycle length and a 25-year time horizon; there were three main health states: dead, alive pre-progression, alive post-progression. Those in pre-progression were further subdivided according to their best overall response, which could be any one of three categories. The distribution between best overall response states was treatment specific and assumed to apply to patients over their entire PFS.
Survival Modeling
The company used the HRs from the NMAs to generate estimates of life-years gained under different treatments.
To generate a survival curve for any treatment compared with LEN-DEX, Takeda took the NMA HR for the comparator vs. LEN-DEX and applied this to covariate-adjusted fits for the LEN-DEX arm of the TMM-1 trial (an exponential fit from 5 months for OS and a gamma fit for PFS). The life-years gained in pre-and post-progression for 'X' were estimated from the area under these newly generated OS and PFS curves. This procedure forces an exponential (OS) or gamma (PFS) curve shape on the comparator, but there is no a priori reason to expect that the observed curve for the comparator will conform to a distribution that fits a treatment regimen with a differing mechanism of action. The resulting survival curves from this procedure may be implausible and/or bear little relationship to the observed curves found in published studies, as was the case here for BORT-DEX in second-line treatment.
In addition to suggesting IXA-LEN-DEX as a secondline treatment for RRMM, Takeda's first submission proposed IXA-LEN-DEX as an option for third-line therapy instead of LEN-DEX. For this analysis, Takeda employed OS and PFS survival data from the TMM-1 trial. The issues with the use of more or less mature data have been discussed above. The appraisal committee considered that the use of data was inappropriate and that the most mature data available should have been used for the analyses.
Cost Evaluation
In their base case, the estimates of the incremental costeffectiveness ratio (ICER) by the company are outside NICE norms for willingness to pay for both second-and third-line therapies. Because of flaws in the company's NMA, and taking into consideration other issues (e.g., disposition of best overall response states in PFS, utility values, and post-treatment costing), the ERG considered the face validity of the ICERs to be poor, especially for the second-line indication. Using the HRs obtained from the ERG's own NMA comparing IXA-LEN-DEX with BORT-DEX, the ERG concluded that IXA-LEN-DEX is dominated by BORT-DEX in patients with one prior therapy.
Outcome Following First Appraisal Committee
At the first appraisal meeting (March 2017), the committee was not convinced that IXA-LEN-DEX if used in the NHS as second-or third-line therapies for RRMM would represent good value for money. The committee was also not persuaded that entering IXA-LEN-DEX into the CDF would alleviate model uncertainty sufficiently to allow a reasonably robust estimate of an ICER for IXA-LEN-DEX in second-or third-line therapies.
Company's Subsequent Submissions, Evidence
Review Group Critique, and Outcomes Following Appraisal Committees
Second Submission
Takeda's second submission dropped IXA-LEN-DEX as second line therapy and re-positioned IXA-LEN-DEX as a third-or fourth-line therapy, with LEN-DEX as the relevant comparator. In this second submission, the submitted evidence came appropriately from patients who had received two or more previous therapies. Furthermore, the company now used the most mature data available from TMM-1 and introduced a patient access scheme, which considerably reduced the ICER estimate and improved the apparent cost effectiveness of IXA-LEN-DEX. Even with more mature data there remained considerable uncertainties regarding which, if any, parametric models of OS and PFS provided well-fitting models that in extrapolation generated clinically plausible scenarios for OS and for partitioning of survival between pre-and post-progression survival. Because the OS data were so immature, it was impossible to establish best parametric models on the basis of information criteria (AIC BIC). The company assumed proportional hazards between LEN-DEX and IXA-LEN-DEX and selected gamma models for PFS and Weibull models for OS. Surprisingly, the PFS gamma model for the two or more prior therapies population receiving IXA-LEN-DEX generated notably less progression than was seen for the gamma model previously selected by Takeda for the one prior therapy population; the ERG considered that this may represent a clinically implausible scenario. A further difficulty arose in the extrapolation of the gamma PFS model for the two or more prior therapies population in that it eventually generated more live non-progressed patients than there were live patients predicted by the company's OS model. This situation was avoided if Weibull models were selected for both PFS and OS; however, now the split between pre-and post-progression survival became heavily in favor of post-progression gain, which again some might consider clinically implausible in a heavily pre-treated population. These difficulties mainly stem from the immaturity of the OS data, and should be alleviated somewhat with extended follow-up. A major assumption in the company modeling was that the OS advantage for IXA-LEN-DEX over LEN-DEX calculated from data for the 'observed' period of about 30 months would be maintained throughout the further 23 years of the economic model; the ERG suggested this could be an optimistic assumption. The ERG explored alternative assumptions about costs incurred by treatment and the quality-of-life decrement post-progression; these explorations tended to inflate the ICER estimate. The panobinostat regimen (PAN-BORT-DEX) was again excluded as a comparator. At a second appraisal meeting (July 2017), the committee remained unconvinced that IXA-LEN-DEX provided good value for money within the NHS, and was not persuaded that the drug should be made available via the CDF.
Third Submission
A third submission from Takeda proposed that IXA-LEN-DEX be considered for the CDF. The company proposed a confidential commercial access agreement and made some further modifications to inputs into their economic model.
At the request of NICE, the ERG undertook analysis of potentially relevant information external to the TMM-1 trial for the purpose of gaining some independent estimates of the likely 10-year survival for patients with RRMM receiving third-or fourth-line treatment in TMM-1, and to gauge the relative contributions from pre-and post-progression survival. Takeda and NICE suggested Dimopoulos et al. [13] as an external data source; in this publication, PFS and OS were reported for LEN-DEX patients pooled from two RCTs (MM-010 and MM-009) [9, 10] . This study provided more patients (n = 353) with longer follow-up (5 years) than were available from TMM-1. The ERG analyzed this study using the methods described above. A gamma model of OS provided the best fit and predicted a 10-year OS of * 5%, which corresponded reasonably well with the company's Weibull model of OS. Using a gamma model for OS and lognormal model for PFS, the pre-/postprogression split was approximately 0.47/0.53 and the mean OS was about 3.7 years. As a proxy for post-progression survival, the ERG also analyzed data reported for 1097 patients (pooled from three studies) followed for about 4 years presented in the NICE pomalidomide-lowdose DEX appraisal (TA338) [14] . These patients would approximately correspond to TMM-1 patients who had progressed because we can assume that people progressing after IXA-LEN-DEX or LEN-DEX would be offered a subsequent line of treatment with pomalidomide-DEX (pomalidomide plus low-dose DEX). Gamma models provided the best fits for both PFS and OS and the latter predicted a mean survival of about 1.61 years, moderately less than the 1.96-year estimate from the Dimopoulos et al. analysis. At a third appraisal meeting (October 2017), the committee concluded that there were substantial uncertainties associated with estimates of survival of patients receiving IXA-LEN-DEX as third-or fourth-line therapies and that under the proposed commercial access agreement in the CDF there was a reasonable expectation these might be resolved sufficiently to be able to gauge the cost effectiveness of this treatment.
Final Outcome: National Institute of Health and Care Excellence Guidance
On 7 February, 2018, NICE guidance [15] was issued as follows: ''Ixazomib, with lenalidomide and dexamethasone, is recommended for use within the Cancer Drugs Fund as an option for treating multiple myeloma in adults only if: they have already had 2 or 3 lines of therapy and the conditions in the managed access agreement for ixazomib are followed''. Although licensed for the treatment of patients who have received at least one previous therapy, the Appraisal Committee believed IXA triple therapy is likely to be used ''only for people who have already had 2 or 3 lines of therapy''. In focussing on this population of patients with myeloma, the committee considered that the ongoing TMM-1 RCT indicated that, relative to LEN plus DEX alone, IXA triple therapy increases the length of time patients live without disease progression. Furthermore, the committee judged that although there were promising interim results from TMM-1, it was not yet clear whether IXA triple therapy prolongs life. At the price agreed in a commercial access agreement, the committee concluded that IXA triple therapy had the potential to be cost effective for the two or three prior therapies population (ICER of £31,691/quality-adjusted life-years gained compared with LEN plus DEX alone), but that more evidence was required to reduce clinical uncertainties and that it could therefore be recommended ''for use within the Cancer Drugs Fund while further data are collected from the clinical trial, and through the Systemic Anti-Cancer Therapy dataset''.
